We are live on ! Find out more
PC

Polar Capital Portfolio holdings

AUM $13.5B
1-Year Est. Return 55.9%
This Fund
S&P 500
This Quarter Est. Return
+7.6%
1 Year Est. Return
+55.9%
3 Year Est. Return
+127.44%
5 Year Est. Return
+269.08%
10 Year Est. Return
–
AUM
$8.89B
AUM Growth
+$1.45B
Cap. Flow
+$1.09B
Cap. Flow %
12.29%
Top 10 Hldgs %
26.12%
Holding
266
New
39
Increased
114
Reduced
52
Closed
27

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$63.8M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$50M
3
VR
Validus Hold Ltd
VR
+$44.1M
4
PBYI icon
Puma Biotechnology
PBYI
+$33.5M
5
BIO icon
Bio-Rad Laboratories Class A
BIO
+$30.4M

Top Sells

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$59.3M
2
DHR icon
Danaher
DHR
+$44.2M
3
HOLX
Hologic
HOLX
+$42M
4
BDX icon
Becton Dickinson
BDX
+$40.7M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$38.7M

Sector Composition

Rank Sector Weight
1 Financials 21.97%
2 Healthcare 21.33%
3 Technology 19.13%
4 Communication Services 9.13%
5 Industrials 6.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AUY
201
DELISTED
Yamana Gold, Inc.
AUY
$3.28M 0.04%
1,202,181
-644,273
-35% -$1.71M
NSTG
202
DELISTED
NanoString Technologies, Inc.
NSTG
$3.23M 0.04%
200,000
-25,000
-11% -$386K
ARRY
203
DELISTED
Array Biopharma Inc
ARRY
$3.08M 0.03%
+250,000
New +$2.32M
TSM icon
204
TSMC
TSM
$2.09T
$3.03M 0.03%
80,768
– –
HMSY
205
DELISTED
HMS Holdings Corp.
HMSY
$2.98M 0.03%
+150,000
New +$2.79M
CALD
206
DELISTED
Callidus Software, Inc.
CALD
$2.89M 0.03%
117,388
-100,069
-46% -$2.43M
NMFC icon
207
New Mountain Finance
NMFC
$646M
$2.85M 0.03%
200,000
+50,000
+33% +$710K
ACAD icon
208
Acadia Pharmaceuticals
ACAD
$4.25B
$2.83M 0.03%
75,000
-100,000
-57% -$3.25M
PTGX icon
209
Protagonist Therapeutics
PTGX
$8.75B
$2.65M 0.03%
150,000
+50,000
+50% +$692K
ACM icon
210
Aecom
ACM
$9.07B
$2.64M 0.03%
71,655
-211,111
-75% -$6.94M
RARX
211
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$2.56M 0.03%
175,000
+100,000
+133% +$1.51M
MULE
212
DELISTED
MuleSoft, Inc.
MULE
$2.52M 0.03%
125,100
+95,253
+319% +$2.12M
MIXT
213
DELISTED
MIX TELEMATICS LIMITED
MIXT
$2.44M 0.03%
245,454
– –
EXEL icon
214
Exelixis
EXEL
$13.9B
$2.42M 0.03%
100,000
-90,000
-47% -$2.4M
MCO icon
215
Moody's
MCO
$81.7B
$2.4M 0.03%
17,212
– –
HDB icon
216
HDFC Bank
HDB
$119B
$2.27M 0.03%
94,272
-23,340
-20% -$555K
MTLS
217
Materialise
MTLS
$379M
$2.04M 0.02%
141,662
– –
BSFT
218
DELISTED
BroadSoft, Inc.
BSFT
$1.88M 0.02%
37,396
– –
TWTR
219
DELISTED
Twitter, Inc.
TWTR
$1.79M 0.02%
106,125
– –
ANAB icon
220
AnaptysBio
ANAB
$1.6B
$1.75M 0.02%
50,000
+20,000
+67% +$539K
SSTI icon
221
SoundThinking
SSTI
$107M
$1.31M 0.01%
+97,868
New +$1.17M
WWE
222
DELISTED
World Wrestling Entertainment
WWE
$1.3M 0.01%
+55,580
New +$1.19M
SMMT icon
223
Summit Therapeutics
SMMT
$10.9B
$1.25M 0.01%
+100,000
New +$1.3M
VRNA
224
DELISTED
Verona Pharma
VRNA
$1.17M 0.01%
+75,917
New +$1M
CFG icon
225
Citizens Financial Group
CFG
$30.4B
$1.14M 0.01%
30,056
+1,820
+6% +$63.7K
7 8
9
10 11

Similar funds

ECM
ETrade Capital Management Arlington, Virginia $5.37B AUM 10.84% 1-Year Est. Return
FAAS
First Allied Advisory Services San Diego, California $2.98B AUM 15.89% 1-Year Est. Return
WAM
Wealthspire Advisors (Maryland) Potomac, Maryland $2.84B AUM 10.91% 1-Year Est. Return
FS
Feinberg Stephen $2.61B AUM 15.12% 1-Year Est. Return
NIMC
NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return
TI
TT International London, United Kingdom $1.94B AUM
VIM
Veritas Investment Management London, United Kingdom $1.65B AUM 25.54% 1-Year Est. Return
PS
Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return

Polar Capital's Q3 2017 Portfolio in Review

As of Q3 2017, Polar Capital held 266 positions worth $8.89B, up 20% from $7.43B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Polar Capital deployed $1.09B of net new capital in Q3 2017, opening 39 new positions and adding to 114 existing holdings. Its largest new stake was Puma Biotechnology: 360,000 shares worth $43.1M.

By sector, the portfolio is most concentrated in Financials at 22% of assets, down from 23% a quarter earlier, followed by Healthcare and Technology.

On the sell side, the largest reduction was Medtronic, an estimated $59.3M trimmed.

  • Polar Capital's largest Q3 2017 buy was Puma Biotechnology: 360,000 shares worth $43.1M.
  • Polar Capital added most to Amgen in Q3 2017, an estimated $63.8M increase.
  • Polar Capital's biggest Q3 2017 reduction was Medtronic, cutting an estimated $59.3M.
  • Polar Capital fully exited Hologic in Q3 2017, selling an estimated $42M.
  • Polar Capital's ten largest holdings make up 26% of its $8.89B portfolio in Q3 2017.
  • Polar Capital opened 39 new positions and closed 27 in Q3 2017.
  • Polar Capital's portfolio value rose 20% quarter-over-quarter to $8.89B.

Based on Polar Capital's 13F filing for Q3 2017, filed 14 Nov 2017.